Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826, Seoul, Republic of Korea.
Can J Vet Res. 2020 Oct;84(4):272-282.
The objective of this study was to compare the efficacy of commercially available porcine circovirus type 2 (PCV2) and vaccines. A total of 80 pigs was randomly divided into 6 treatment groups; 4 of the groups each received a different vaccine as well as a dual challenge. The remaining 2 groups were used as controls, 1 of which also received a dual challenge. Two of the 4 groups of pigs were administered 2 monovalent vaccines (designated as either monovalent vaccine A or B) of PCV2 at 7 days old and of at 21 days old. The remaining 2 vaccinated groups of pigs received a bivalent vaccine (designated as either bivalent vaccine A or B) of PCV2 and at 21 days old. All 4 vaccinated groups were challenged with at 42 days old [-14 d post-challenge (dpc)], followed by a PCV2d challenge at 56 days old (0 dpc). All 4 vaccinated/challenged groups displayed a reduction in clinical signs, PCV2d viremia, nasal shedding of , and lung lesions compared with pigs in the unvaccinated and challenged groups. Vaccination and challenge improved growth performance and increased the immunologic responses (- and PCV2-specific antibodies and interferon-γ-secreting cells) when compared to pigs in the unvaccinated/challenged groups. Pigs in groups vaccinated with either a monovalent or bivalent vaccine A treatment and challenge produced a larger amount of - and PCV2d-specific interferon-γ-secreting cells within the pigs and simultaneously reduced the nasal shedding of and PCV2d viremia compared with groups vaccinated with either a monovalent or bivalent vaccine B treatment and challenge. Both the bivalent vaccines and the respective monovalent vaccines were efficacious against a dual challenge of and PCV2d.
本研究旨在比较市售猪圆环病毒 2 型（PCV2）疫苗的效力。将 80 头猪随机分为 6 个治疗组；其中 4 个组分别接种了不同的疫苗，并进行了双重挑战。其余 2 个组作为对照组，其中 1 个也进行了双重挑战。其中 2 个猪组在 7 日龄和 21 日龄时接种了 2 种单价疫苗（分别命名为单价疫苗 A 或 B）的 PCV2；其余 2 个接种疫苗的猪组在 21 日龄时接种了 PCV2 和 的双价疫苗（分别命名为双价疫苗 A 或 B）。所有 4 个接种疫苗的组均在 42 日龄时进行了 攻毒挑战[-14 天攻毒后（dpc）]，随后在 56 日龄时进行了 PCV2d 攻毒（0 dpc）。与未接种和攻毒的猪相比，所有 4 个接种疫苗/攻毒的组的临床症状、PCV2d 病毒血症、鼻拭子中 的脱落量和肺部病变均减少。与未接种/攻毒的猪相比，接种疫苗和攻毒可提高生长性能，并增加 -和 PCV2 特异性抗体以及干扰素-γ分泌细胞的免疫应答。用单价或双价疫苗 A 处理和攻毒的猪产生的 量和 PCV2d 特异性干扰素-γ分泌细胞量更大，同时减少了鼻拭子中 的脱落量和 PCV2d 病毒血症，与用单价或双价疫苗 B 处理和攻毒的猪相比。双价疫苗和各自的单价疫苗对 和 PCV2d 的双重挑战均有效。
